Alirocumab Cuts CV Absolute Risk the Most for Those With Diabetes
TUESDAY, July 16, 2019 -- Among those receiving alirocumab in addition to statin therapy to reduce the risk for another cardiovascular event after a recent acute coronary syndrome, absolute risk reduction is greater for those with diabetes,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | Pharmaceuticals | Statin Therapy